Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Active, not recruiting Not applicable

Eye-tracking Working Memory Training in Children and Youth With Severe Cerebral Palsy

NCT06918379 · tracked via the Priya Life Science Belgium tracker
Sponsor
Phase
Not applicable
Started
2024-11-04
Last updated
2025-04-13

Condition(s) studied

Cerebral Palsy

Investigational drug(s) / intervention(s)

Cogmed Working Memory Training (CWMT)

Cogmed Working Memory Training (CWMT): This is an intensive, eye-tracking working memory (WM) training in school-aged children and young adults with severe cerebral palsy. The Cogmed Working Memory Training (CWMT) software was used as intervention software. The CWMT is adaptive, meaning, it becomes either progressively more difficult or less difficult depending on participants' performance. When a participant completes a trial correctly, the level will increase for the next trial. When a participant makes an error, the next trial will either remain on the same level or decrease in level depending on the type of error made. The CWMT program thus adapts on an individualized basis to participant's performance, allowing for training to occur at or close to an individual's highest capacity. Participants with severe cerebral palsy, users of eye-tracking technology, trained for \~30 minutes, 5 days a week for 5 weeks, i.e. 25 training sessions in total.

Study summary

People with severe cerebral palsy (CP) who are nonverbal and unable to control conventional computer interfaces due to the severe limitations in hand control benefit from eye-tracking technology as access method to Augmentative and Alternative Communication (AAC) devices and to computers for education and leisure. Research has put forward the large demands that the use of AAC puts on working memory (WM), defined as our ability to temporarily store information that is no longer perceptually present, allowing us to manipulate it for meaningful goal-directed behaviour.

People with CP show significant WM deficits, which affect learning capacities and academic achievement, including impaired language and reading comprehension, and arithmetic difficulties. Cogmed WM training (CWMT) is a computerized software with a great potential to boost WM capacity and overall cognitive functioning. Its effectiveness is influenced by the theory of neuroplasticity due to repeated mental tasks.

To date, no prior study investigated the effectiveness of CWMT in children and youth with severe CP who rely on eye-tracking technology for daily-life functioning. This is the first trial that aims to explore the impact of a 5-week CWMT on WM capacity and its near-transfer effect (trained and untrained WM tasks), far-transfer effect (other cognitive abilities, quality of eye movements and behaviour) and retention 3-months post intervention.

Eligibility

Sex
ALL
Min age
7 Years
Max age
21 Years
Healthy volunteers
No
Inclusion Criteria: 1. official CP diagnosis by a paediatric neurologist 2. 7-21 years old 3. users of eye-tracking technology for computer access and AAC 4. classified as level IV-V on the Manual Ability Classification System (MACS) 5. classified as level I-III on the Eye-pointing Classification Scale (EpCS) 6. ability to understand and follow instructions, assessed using the Dichotomous Choice Screen Exclusion Criteria: 1. severe visual and/or hearing impairment 2. presence of photosensitive epilepsy

Primary outcome measure(s)

  • Mean Improvement Index — 5 weeks
    The Mean Improvement Index is a metric that assesses the changes in WM span during training; and reflects near-transfer effect of WM Training on trained WM tasks. A Mean Improvement Index of ≥14 has been reported as an improvement cut-off value. The Mean Improvement Index is a built-in compliance/progress measure, calculated by subtracting the Start Index (results of day 2 and 3 of training) from the Max Index (results from the two best training days). Higher Improvement Index scores indicate greater compliance and progress with CWMT.

Trial sites (1)

FacilityCityRegionStatus
Ten Dries Deinze West-Vlaanderen
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06918379 on ClinicalTrials.gov ↗ ← All trials in Belgium